만성 변비 : 시장 인사이트, 역학 및 시장 예측(2036년)

Chronic Constipation Insights and Trends

• A significant proportion of the chronic constipation burden is associated with factors such as poor dietary habits, low fiber intake, sedentary lifestyle, aging, neurological disorders, metabolic conditions, medication use, and gastrointestinal motility dysfunction, highlighting the need for integrated disease management, lifestyle modification, early diagnosis, and targeted therapeutic approaches to improve bowel function and patient quality of life.
• The treatment of chronic constipation includes pharmacological approaches such as Linaclotide, Plecanatide, and Prucalopride, which improve intestinal fluid secretion and gastrointestinal motility to relieve symptoms and enhance bowel movement frequency, while dietary management and lifestyle interventions remain important components of long-term care.
• Various diagnostic and clinical assessment approaches for chronic constipation include symptom-based Rome IV criteria, bowel movement frequency assessment, stool consistency evaluation, colonic transit studies, anorectal manometry, and quality-of-life assessments. These support accurate diagnosis, identification of underlying causes, and tailored treatment strategies across different patient populations.
• The chronic constipation treatment landscape continues to evolve with several approved and emerging targeted therapies. Key approved therapies include Linaclotide, Plecanatide, and Prucalopride, while emerging therapies such as Tenapanor are being investigated to further improve gastrointestinal motility, symptom control, and long-term disease management.

DelveInsight's 'Chronic Constipation - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of chronic constipation, historical and forecasted epidemiology, as well as the chronic constipation market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chronic Constipation market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates chronic constipation patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in chronic constipation and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Chronic Constipation Market

Rising Chronic Constipation Prevalence

The increasing prevalence of chronic constipation, especially among preschool-aged children, is driven by factors such as poor dietary habits, low fiber intake, inadequate hydration, sedentary lifestyles, toilet-training difficulties, and growing awareness and diagnosis of gastrointestinal disorders, thereby contributing to market expansion.

Rising Opportunities in Targeted Iron Therapies

Advancing understanding of gastrointestinal motility disorders, intestinal fluid regulation, and gut-brain interactions in chronic constipation is creating growing opportunities for drug developers to focus on targeted therapies that improve bowel function, reduce symptom burden, and enhance patient quality of life.

Chronic Constipation Understanding and Treatment Algorithm

Chronic Constipation Overview and Diagnosis

Chronic constipation is a common gastrointestinal disorder characterized by infrequent bowel movements, difficulty passing stools, or a sensation of incomplete evacuation persisting for several weeks or longer. The condition can range from mild to severe and is often associated with symptoms such as abdominal discomfort, bloating, hard stools, and excessive straining during defecation. Chronic constipation may result from inadequate dietary fiber intake, dehydration, sedentary lifestyle, medication use, or underlying neurological and gastrointestinal disorders. Diagnosis is primarily based on clinical evaluation and symptom history.

Chronic constipation is diagnosed through medical history, physical examination, and assessment of bowel habits and symptoms. Physicians evaluate stool frequency, stool consistency, difficulty during defecation, sensation of incomplete evacuation, and associated symptoms such as abdominal discomfort or bloating. Diagnostic tests may include blood tests to rule out metabolic or hormonal disorders, stool tests, and imaging studies when necessary. In patients with persistent or severe symptoms, specialized investigations such as colonoscopy, anorectal manometry, balloon expulsion testing, or colonic transit studies may be performed to identify underlying structural or functional abnormalities.

Chronic Constipation Treatment

The primary goals of chronic constipation treatment are to improve bowel movement frequency, relieve constipation-related symptoms, restore normal gastrointestinal motility, and enhance patient quality of life. Management typically includes lifestyle and dietary modifications, increased fiber and fluid intake, behavioral interventions, and pharmacologic therapies. Commonly used treatments include osmotic and stimulant laxatives, while prescription therapies such as Linaclotide, Plecanatide, and Prucalopride are used in patients with persistent symptoms. Emerging therapies such as Tenapanor are being developed to further improve gastrointestinal motility and long-term symptom control in chronic constipation patients.

Chronic Constipation Unmet Needs

The section "unmet needs of Chronic Constipation" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Inadequate symptom relief with current therapies

2. High recurrence and chronic disease burden

3. Delayed diagnosis and underreporting

4. Poor patient adherence to long-term treatment, and others.....

Chronic Constipation Epidemiology

Key Findings from Chronic Constipation Epidemiological Analysis and Forecast

• Chronic Constipation accounts for more than 95% of cases of constipation in healthy children aged one year and older.
• Among the 7MM, the United States accounted for the highest number of prevalent cases of Chronic Constipation in 2025.
• Chronic Constipation is particularly common among preschool-aged children.
• According to findings, the prevalence of chronic constipation was reported to be 5.5% in the US, according to the Rome III criteria, and it was found to be 2.1% based on medical consultations in Japan.
• Chronic Constipation demonstrates a clear female predominance, with women experiencing the condition at roughly twice the rate of men across most demographic studies.

Chronic Constipation Drug Chapters & Competitive Analysis

The chronic constipation drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the chronic constipation treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the chronic constipation therapeutics market.

Approved Therapies for Chronic Constipation

Linaclotide (LINZESS): Ironwood/AbbVie

LINZESS, developed by Ironwood Pharmaceuticals in collaboration with AbbVie, is an oral guanylate cyclase-C (GC-C) agonist approved by the US FDA in 2012 for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), with later label expansion for pediatric functional constipation. By increasing intestinal fluid secretion and accelerating gastrointestinal transit, LINZESS helps improve bowel movement frequency and reduce abdominal symptoms associated with chronic constipation, establishing itself as a leading targeted therapy in the gastrointestinal disorders market.

Plecanatide (TRULANCE): Synergy Pharmaceuticals/ Bausch Health Companies

TRULANCE, developed by Synergy Pharmaceuticals and marketed by Bausch Health Companies, is an oral guanylate cyclase-C (GC-C) receptor agonist approved by the US FDA in 2017 for the treatment of adults with CIC and later for IBS-C. As a synthetic analog of uroguanylin, TRULANCE works by increasing intestinal fluid secretion and accelerating gastrointestinal transit, thereby improving bowel movement frequency and reducing constipation-related symptoms. Its targeted mechanism and favorable tolerability profile have positioned TRULANCE as an important therapeutic option in the chronic constipation treatment landscape.

Chronic Constipation Pipeline Analysis

Tenapanor (IBSRELA): Ardelyx

Tenapanor is a first-in-class, orally administered small-molecule inhibitor of the sodium/hydrogen exchanger 3 (NHE3) developed by Ardelyx. By inhibiting NHE3 in the gastrointestinal tract, tenapanor reduces sodium absorption, increases intestinal fluid secretion, and accelerates bowel transit, thereby improving stool frequency and consistency. Its novel mechanism of action differentiates it from traditional laxatives and secretagogues. Tenapanor is approved in the United States under the brand name IBSRELA for irritable bowel syndrome with constipation (IBS-C) and is being explored as a potential treatment option for patients with chronic constipation who remain inadequately controlled with conventional therapies.

Chronic Constipation Key Players, Market Leaders, and Emerging Companies

• Ironwood
• AbbVie
• Synergy Pharmaceuticals
• Bausch Health Companies
• Shire
• Takeda
• EA Pharma
• Mochida Pharmaceutical, and others

Chronic Constipation Drug Updates

• In May 2026, Ironwood Pharmaceuticals reported strong Q1 2026 performance for LINZESS, with US net sales reaching USD 273 million, reflecting a 97% year-over-year increase primarily driven by improved net pricing.

Chronic Constipation Market Outlook

The chronic constipation market is undergoing steady evolution, moving beyond conventional laxatives toward targeted therapies that improve gastrointestinal motility, intestinal fluid secretion, and bowel function. The growing development of novel prokinetic agents, secretagogues, and gut-targeted therapies reflects increasing focus on addressing the underlying pathophysiology of chronic constipation rather than providing only symptomatic relief. These advancements are strengthening clinical interest in next-generation therapies and reshaping the competitive landscape.

With the continued advancement of pipeline candidates such as Tenapanor and other emerging therapies, the chronic constipation treatment landscape is expanding similarly to other chronic gastrointestinal disorders, where innovation is driving broader therapeutic development. The United States is expected to remain a major market due to the high disease burden, increasing prevalence among pediatric and elderly populations, growing awareness, and improved diagnosis and treatment accessibility.

Overall, the introduction of differentiated therapies, increasing research into gastrointestinal motility disorders, rising healthcare awareness, and growing demand for effective long-term treatment options are expected to drive growth in the chronic constipation market during the forecast period, creating significant commercial opportunities for both approved and emerging therapies.

• According to the estimates, the United States accounted for the largest share of the chronic constipation market among the major markets during the study period.
• The chronic constipation market is shifting from conventional laxatives toward targeted therapies that enhance gastrointestinal motility and intestinal fluid secretion, with novel agents such as Tenapanor driving innovation through improved symptom control and quality-of-life outcomes.
• The US leads the chronic constipation market in terms of research activity and revenue generation, while Europe and Japan are experiencing steady growth driven by increasing disease awareness, improved diagnosis, and continued therapeutic innovation.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chronic Constipation (2022-2036 Forecast)

The chronic constipation market comprises laxatives, stool softeners, prokinetic agents, secretagogues, rectal therapies, and emerging targeted therapies, each addressing distinct aspects of impaired bowel motility, stool consistency, and gastrointestinal dysfunction in chronic constipation.

• Laxatives and stool softeners: Conventional therapies such as polyethylene glycol, bisacodyl, senna, lactulose, and docusate sodium remain the foundation of chronic constipation management by promoting bowel movements and improving stool passage, although long-term efficacy may vary among patients.
• Secretagogues and chloride channel activators: Agents such as linaclotide, plecanatide, and lubiprostone work by increasing intestinal fluid secretion and improving stool consistency, representing an important advancement in chronic constipation treatment.
• Emerging targeted therapies: Novel therapies targeting gut motility, enteric nervous system signaling, and gastrointestinal function are being explored to provide improved efficacy, long-term symptom control, and better tolerability in chronic constipation management.

Laxatives and secretagogues currently dominate the chronic constipation treatment landscape, while prokinetic and emerging targeted therapies are shaping the future innovation pipeline and driving next-generation therapeutic development in chronic constipation.

Chronic Constipation Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the chronic constipation market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in chronic constipation is expected to vary across established prescription therapies and emerging gastrointestinal motility-enhancing agents. Approved therapies such as Linaclotide, Plecanatide, and Prucalopride are likely to maintain significant uptake due to their efficacy in improving bowel movements and symptom relief. Emerging therapies, including Tenapanor, are anticipated to gain gradual uptake owing to their potential to further enhance gastrointestinal motility and address unmet needs in chronic constipation management.

Chronic Constipation Therapies Price Scenario & Trends

Pricing and analogue assessment of Chronic Constipation therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Chronic Constipation

To keep up with the Chronic Constipation market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Chronic Constipation emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Chronic Constipation, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Harvard Medical School, University of Nottingham, and Gastroenterology and Motility Centers, etc., were contacted. Their opinion helps understand and validate current and emerging Chronic Constipation therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Chronic Constipation.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Chronic Constipation, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of chronic constipation, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the chronic constipation market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM chronic constipation market.

Report Insights

• Chronic Constipation Patient Population Forecast
• Chronic Constipation Therapeutics Market Size
• Chronic Constipation Pipeline Analysis
• Chronic Constipation Market Size and Trends
• Chronic Constipation Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Chronic Constipation Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Constipation Treatment Addressable Market (TAM)
• Chronic Constipation Competitive Landscape
• Chronic Constipation Major Companies Insights
• Chronic Constipation Price Trends and Analogue Assessment
• Chronic Constipation Therapies Drug Adoption/Uptake
• Chronic Constipation Therapies Peak Patient Share analysis

Report Assessment

• Chronic Constipation Current Treatment Practices
• Chronic Constipation Unmet Needs
• Chronic Constipation Clinical Development Analysis
• Chronic Constipation Emerging Drugs Product Profiles
• Chronic Constipation Market Attractiveness
• Chronic Constipation Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the chronic constipation market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of chronic constipation?
• What are the disease risks, burdens, and unmet needs of chronic constipation? What will be the growth opportunities across the 7MM concerning the patient population with chronic constipation?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of chronic constipation? What are the current guidelines for treating chronic constipation in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the chronic constipation market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Constipation

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology of Chronic Constipation

6. Chronic Constipation Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (by Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of Chronic Constipation by Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of Chronic Constipation by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Chronic Constipation

• 7.1. Introduction
• 7.2. Signs and Symptoms of Chronic Constipation
• 7.3. Causes of Chronic Constipation
• 7.4. Risk Factors of Chronic Constipation
• 7.5. Pathophysiology of Chronic Constipation
• 7.6. Diagnosis of Chronic Constipation

8. Treatment of Chronic Constipation

• 8.1. Algorithm for the treatment of Chronic Constipation
• 8.2. Guidelines for the treatment of Chronic Constipation

9. Epidemiology and Patient Population of Chronic Constipation

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Diagnosed Prevalent Cases of Chronic Constipation in the 7MM
• 9.4. The United States
  • 9.4.1. Total Prevalent Cases of Chronic Constipation in the US
  • 9.4.2. Diagnosed Prevalent Cases of Chronic Constipation in the US
  • 9.4.3. Gender-Specific Diagnosed Prevalent Cases of Chronic Constipation in the US
  • 9.4.4. Age-Specific Diagnosed Prevalent Cases of Chronic Constipation in the US
• 9.5. EU4 and the UK
  • 9.5.1. Total Prevalent Cases of Chronic Constipation in EU4 and the UK
  • 9.5.2. Diagnosed Prevalent Cases of Chronic Constipation in EU4 and the UK
  • 9.5.3. Gender-Specific Diagnosed Prevalent Cases of Chronic Constipation in EU4 and the UK
  • 9.5.4. Age-Specific Diagnosed Prevalent Cases of Chronic Constipation in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Prevalent Cases of Chronic Constipation in Japan
  • 9.6.2. Diagnosed Prevalent Cases of Chronic Constipation in Japan
  • 9.6.3. Gender-Specific Diagnosed Prevalent Cases of Chronic Constipation in Japan
  • 9.6.4. Age-Specific Diagnosed Prevalent Cases of Chronic Constipation in Japan

10. Patient Journey of Chronic Constipation

11. Marketed Therapies

• 11.1. Marketed Competitive Landscape of Chronic Constipation
• 11.2. Linaclotide (LINZESS): Ironwood/AbbVie
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views
• 11.3. Plecanatide (TRULANCE): Synergy Pharmaceuticals/ Bausch Health Companies
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst's Views

. Note: List to be continued in the report

12. Emerging Drugs

• 12.1. Emerging Competitive Landscape of Chronic Constipation
• 12.2. Tenapanor (IBSRELA): Ardelyx
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst's Views

. Note: List to be continued in the report

13. Chronic Constipation: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of Chronic Constipation
• 13.3. Key Market Forecast Assumptions
  • 13.3.1. Cost Assumptions
  • 13.3.2. Pricing Trends
  • 13.3.3. Analogue Assessment
  • 13.3.4. Launch Year and Therapy Uptakes
• 13.4. Conjoint Analysis of Chronic Constipation
• 13.5. Total Market Size of Chronic Constipation in the 7MM
• 13.6. Total Market Size of Chronic Constipation by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of Chronic Constipation in the United States
  • 13.7.2. Total Market Size of Chronic Constipation by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of Chronic Constipation in EU4 and the UK
  • 13.8.2. Total Market Size of Chronic Constipation by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of Chronic Constipation in Japan
  • 13.9.2. Total Market Size of Chronic Constipation by Therapies in Japan

14. Unmet Needs of Chronic Constipation

15. SWOT Analysis of Chronic Constipation

16. KOL Views of Chronic Constipation

17. Market Access and Reimbursement of Chronic Constipation

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of Chronic Constipation Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight